Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.54 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700440 | 1.00 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL16160645 | 1.00 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1700879 | 1.00 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL17062389 | 0.96 | MAPT (0.50) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL17071336 | 0.91 | MAPT (0.56) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1701073 | 0.89 | MAPT (0.55) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1700739 | 0.89 | MAPT (0.55) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1700736 | 0.89 | MAPT (0.55) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL25307257 | 0.87 | MAPT (0.50) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL28533848 | 0.87 | MAPT (0.52) | MAPTPKMPOLBSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642776-A1 | SALTS AND SOLID FORMS OF SONROTOCLAX INTERMEDIATE | Beone Medicines I GmbH (CH) | 2025-11-05 | — | — | EP | claimed |
| US-20250320207-A1 | Ketal Protected Intermediate for Sonrotoclax and Preparation Method Thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-16 | — | — | US | claimed |
| US-20250320208-A1 | Intermediates of Sonrotoclax and the Method of Preparing the Same | BEONE MEDICINES I GMBH (CH) | 2025-10-16 | — | — | US | claimed |
| CN-119546615-A | Sonrotoclax intermediates and process for their preparation | 百济神州(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119301117-A | Salt and solid forms of Sonrotoclax intermediates | 百济神州(苏州)生物科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119301124-A | Ketal protected intermediates for Sonrotoclax and methods of making the same | 百济神州(苏州)生物科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| WO-2024140692-A1 | SALTS AND SOLID FORMS OF SONROTOCLAX INTERMEDIATE | BEIGENE (SUZHOU) CO., LTD. (CN) | 2024-07-04 | — | — | WO | claimed |
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-12516053-B2 | Bcl-2 inhibitors | BEONE MEDICINES I GMBH (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-4642776-A1 | SALTS AND SOLID FORMS OF SONROTOCLAX INTERMEDIATE | Beone Medicines I GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2011068560-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | MAPT 4241/4885PKM 3944/4885POLB 3669/4885 |
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | BCL2A1, BCL2L1, BCL2L11 | MAPT 4049/4885PKM 3866/4885POLB 4499/4885 |
| US-20250320207-A1 | Ketal Protected Intermediate for Sonrotoclax and Preparation Method Thereof | KCNH3, KCNH1, KCNH2 | MAPT 4788/4885PKM 347/4885POLB 1098/4885 |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 4105/4885PKM 4645/4885POLB 1831/4885 |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 3890/4885PKM 4532/4885POLB 1702/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 4105/4885PKM 4645/4885POLB 1831/4885 |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | MAPT 3942/4885PKM 4422/4885POLB 1384/4885 |
| US-20250320208-A1 | Intermediates of Sonrotoclax and the Method of Preparing the Same | DNMT1, UQCRC2, TOP2B | MAPT 4601/4885PKM 2702/4885POLB 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.